Novo Health Care Service and Encore Surgical Supplies developed the HealPACK as an innovative surgical dressing solution that enhances the post-surgery healing process, delivered to the patient's door for treatment in the comfort of the patient's home.

HealPACK is a convenience pack of premium line of surgical dressing products trusted by physicians nationwide. HealPACK comes with a specifically development HealPACK app that supports the prescription and insurance verification process needed to order the product.

The app also assists with relevant documentation required for proper reimbursement of the dressings. Each physician-prescribed, patient-specific order is shipped directly to the patient, eliminating risks around the interruption of continued care, increasing patient's wound care compliance, and saving physicians' practice time and money.

Miro Kesic, Encore's CEO said, "In a short amount of time, we have become a market leader in empowering physicians to deliver post operative and conservative therapies for their patients. With a great team, advanced technology, and timely execution, Encore has delivered a superior platform to the market. This has resulted in the exponential growth and success of Encore Surgical."

Neall French, Encore's President added, "The next phase in continuing to deliver constant innovation and enhancements, is to align the HealPACK with one the industry's best, in Tiger BioSciences. Tiger has an exceptional leadership team, impressive portfolio of companies, and a relentless mission in delivering superior clinical outcomes for patients."

"The HealPACK and HealAPP is a fantastic addition to Tiger's already impressive Wound Care product offering. Encore Surgical Dressing, LLC will be a new division of Tiger BioSciences that will have access to our vast network of customers in the orthopedic, podiatry as well as plastic surgery divisions. We are looking forward to the continuation of collaboration with Miro's and Nealls's team to ensure that more patients can benefit from our overall product offering," said Oliver Burckhardt, Co-CEO of Tiger BioSciences.